The estimated savings to Medicare during 2015-2020 that resulted from competition with five of the first-to-market biosimilars with skinny labels was $1.5 billion.
Managing adverse events with trastuzumab deruxtecan (Enhertu) in real-world clinical practice is proving trickier than would have been anticipated from clinical trial reports.
The drug was not approved for the treatment of patients with previously treated locally advanced or metastatic nonsmall cell lung cancer harboring HER2 exon 20 insertion mutations.
A clinical trial found that rituximab and cyclophosphamide had similar outcomes for interstitial lung disease associated with connective tissue disorders.